| Literature DB >> 23952712 |
Samdeep K Mouli1, Patrick Tyler, Joseph L McDevitt, Aaron C Eifler, Yang Guo, Jodi Nicolai, Robert J Lewandowski, Weiguo Li, Daniel Procissi, Robert K Ryu, Y Andrew Wang, Riad Salem, Andrew C Larson, Reed A Omary.
Abstract
Nanoparticles (NP) have emerged as a novel class of therapeutic agents that overcome many of the limitations of current cancer chemotherapeutics. However, a major challenge to many current NP platforms is unfavorable biodistribution, and limited tumor uptake, upon systemic delivery. Delivery, therefore, remains a critical barrier to widespread clinical adoption of NP therapeutics. To overcome these limitations, we have adapted the techniques of image-guided local drug delivery to develop nanoablation and nanoembolization. Nanoablation is a tumor ablative strategy that employs image-guided placement of electrodes into tumor tissue to electroporate tumor cells, resulting in a rapid influx of NPs that is not dependent on cellular uptake machinery or stage of the cell cycle. Nanoembolization involves the image-guided delivery of NPs and embolic agents directly into the blood supply of tumors. We describe the design and testing of our innovative local delivery strategies using doxorubicin-functionalized superparamagnetic iron oxide nanoparticles (DOX-SPIOs) in cell culture, and the N1S1 hepatoma and VX2 tumor models, imaged by high resolution 7T MRI. We demonstrate that local delivery techniques result in significantly increased intratumoral DOX-SPIO uptake, with limited off-target delivery in tumor-bearing animal models. The techniques described are versatile enough to be extended to any NP platform, targeting any solid organ malignancy that can be accessed via imaging guidance.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23952712 PMCID: PMC4012535 DOI: 10.1021/nn4023119
Source DB: PubMed Journal: ACS Nano ISSN: 1936-0851 Impact factor: 15.881